Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 127

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 127
---
30, 2025 and December 31, 2024. The Company classified the contingent consideration liability as Level 3 fair value measurements as of June 30, 2025 and December 31, 2024. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated revenue projections and probability of achievement of milestone. Change in the Fair Value of Contingent ConsiderationThe following tables provide a reconciliation of the beginning and ending balances related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):USWM AcquisitionAdamas AcquisitionTotalBalance at December 31, 2024$47,340 $— $47,340 Change in fair value recognized in earnings7,660 — 7,660 Milestone payments(27,295)— (27,295)Reclassification to Other Current Liabilities(27,705)(27,705)Balance at June 30, 2025 (unaudited)$— $— $— USWM AcquisitionAdamas AcquisitionTotalBalance at December 31, 2023$46,400 $7,050 $53,450 Change in fair value recognized in earnings(1,170)(4,280)(5,450)Balance at June 30, 2024 (unaudited)$45,230 $2,770 $48,000 The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:•The Company recorded  a $7.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones for the six months ended June 30, 2025. No expense was recorded during the three months ended June 30, 2025. The Company recorded a $1.9 million gain and a $1.2 million gain due to the change in the fair value of the contingent consideration liabilities for the USWM milestones for the three and six months ended June 30, 2024, respectively. The change in fair value of contingent consideration was primarily due to accretion to the full milestone payment amount with the achievement of the milestones. ONAPGO was approved by the FDA in February 2025 and was launched in April 2025. The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs:

•The Company recorded a $2.5 million gain and a $